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S1
COMPLEX BIOLOGICAL RESPONSES TO DAMAGING AGENTS
Leona D. Samson,  Biological Engineering Division,
Center for Environmental Health Sciences, Massachusetts Institute of 
Technology, USA
Alkylating agents are abundant in our cellular and external environment, 
and they are toxic, mutagenic, and carcinogenic.  Because of their 
toxic properties, certain alkylating agents are also used for cancer 
chemotherapy.  Therefore, it is important to elucidate the constellation 
of different biochemical and genetic pathways by which both normal 
and malignant cells respond to alkylation damage.  Our ultimate goal 
is to develop ways of predicting how certain agents will affect these 
very different target cell populations.  It is well known that a variety 
of DNA repair pathways and cell cycle checkpoint pathways protect 
cells against the toxic effects of alkylation damage.  But now we have 
shown that a multitude of other unexpected pathways are also involved 
in cellular recovery, and our goal is to understand how these cellular 
pathways operate and interact with each other to determine the ultimate 
phenotypic response to such environmental assaults.  We use a variety 
of cellular and animal model systems ranging from bacteria and yeast 
to mice and humans.  We have studied global genomic responses to 
alkylation damage in E. coli and S. cerevisiae, in mouse and human cell 
lines, and in various tissues of exposed mice.  The results demonstrate 
that global cellular responses to alkylation damage are far more complex 
than ﬁ  rst thought and some of the unexpected pathways that protect 
against alkylation-induced toxicity will be presented and discussed. 
S2
CANCER GENE THERAPY: GETTING VECTORS, GENES AND 
T CELLS TO TUMOURS. 
Gregory Daniels, Luis Sanchez-Perez, Timothy Kottke, Rosa Maria Diaz, 
Caroline Cole, Michael Forshaw, Jill Thompson, Michael Gough, Jian Qiao, 
Richard G. Vile, Molecular Medicine Program and Department of Immunology, 
Mayo Clinic, Rochester, Minnesota 55905.  This lecture has been kindly 
sponsored by NTRAC.
Our long term interest is in the development of truly systemic gene delivery systems which do 
not require prior knowledge of the location of sites of metastatic disease to address the most 
challenging aspects of gene therapy of cancer, where accessibility of a tumor is not a pre-
requisite of successful gene delivery/therapy.
We have pursued two separate routes to achieve this goal.  In the ﬁ  rst, we have devised protocols 
in which vectors can be carried to local sites of tumor growth and be released in response to 
externally applied signals (such as drugs) or environmental cues supplied by the biological 
properties of the tumor itself. We have developed the concept of T cell carriers for the gene 
therapy of cancer using the B16ova murine model in which B16 cells stably express the 
ovalbumin model antigen.  Adoptive transfer of OT-1 T cells, transgenic for the T cell receptor 
that recognizes the SIINFEKL epitope of ova in the context of presentation by H2Db+ve 
B16ova cells leads to tumor killing in vivo. To convert the OT-1 T cells into carriers of retroviral 
vectors we have exploited an observation that retroviral particles will adhere to the external 
cell surface without necessarily productively infecting the target cell. OT-1 T cells loaded with 
surface coated retroviral stocks hand the virus off to new target cells in culture dependent upon 
the presence of a functional envelope whose receptor is only poorly, or not, expressed on the T 
cell itself. In addition, adoptive transfer of OT-1 T cells loaded with surface coated retrovirus 
encoding an HSVtk gene led to signiﬁ  cant improvements in survival of mice bearing lung 
metastases of B16ova tumor cells compared to OT-1 cells alone. Therefore, it is possible to 
enhance the therapeutic potential of adoptive T cell transfer by combining tumor localized 
production of cytotoxic retrovirus with the T cells’ natural effector functions.
In the second approach we hypothesised that in situ, inﬂ  ammatory killing of a normal tissue 
from which a tumor derives may generate autoimmune reactivity to self antigens expressed in 
that tissue as well as in the tumor cells. We have now shown that simple intradermal injection 
of 2 plasmids promoted tissue speciﬁ  c, inﬂ  ammatory killing of melanocytes and induced 
an immune response that eradicated systemically established B16 tumors.  The therapeutic 
response was rapidly suppressed in vivo and did not necessarily induce autoimmune disease. 
This is the ﬁ  rst time that deliberate destruction of normal tissue has been used to generate an 
effective immune response against malignant disease. 
In summary, our results show that it will be possible to deliver genes to normal, or tumor, cells 
such that signiﬁ  cant anti tumor therapeutic effects can be achieved even in clinical situations 
where the location of the disease is unknown. 
S3
REPLICATING ADENOVIRUSES THAT TARGET COLON 
CANCER
Christophe Fuerer, Krisztian Homicsko, Alex Lukashev and Richard Iggo.
Oncogene Group, Swiss Institute for Experimental Cancer Research 
(ISREC), 1066 Epalinges, Switzerland.
The Wnt pathway is constitutively activated in colon tumours by 
mutations in the adenomatous polyposis coli and β-catenin genes. We 
have developed adenoviruses that selectively replicate in cells with 
activated Wnt signalling by inserting binding sites for the Tcf family 
of transcription factors in the early promoters of human adenovirus 5. 
When Tcf sites are inserted in the E1A, E1B and E4 promoters, the 
virus shows 100 to 10,000-fold selectivity for cells with activated wnt 
signalling in viral burst and cytopathic effect assays. Despite evidence 
for efﬁ  cacy in vitro, clinical studies with other oncolytic adenoviruses 
have shown that they are safe but lack efﬁ  cacy. To selectively increase 
the toxicity of Tcf-regulated viruses we have expressed the yeast 
cytosine deaminase gene (yCD) after the ﬁ  bre gene in the major late 
transcript using an internal ribosome entry site (IRES). Cytopathic 
effect assays in colon cancer cell lines show that the yCD virus has ~10-
fold increased toxicity in the presence of the prodrug 5-ﬂ  uorocytosine 
(5-FC), which is converted to 5-ﬂ  uorouracil (5-FU) by yCD. Toxicity is 
higher following addition of 5-FC immediately after infection and viral 
burst size is only slightly reduced in the presence of 5-FC, showing that 
expression of yCD as a late gene is compatible with virus replication. 
Systemic therapy with 1011 particles of a Tcf-regulated virus leads to 
a signiﬁ  cant delay in growth of subcutaneous SW620 xenografts, but 
FISH for viral DNA in treated tumours shows that virus spreads poorly 
within the tumour. To achieve cures with oncolytic adenoviruses will 
require concerted approaches to improve virus delivery to the tumour, 
spread within the tumour and killing of tumour cells.
S4
ONCOVEX: A FAMILY OF ONCOLYTIC HERPES SIMPLEX 
VIRUSES OPTIMISED FOR THERAPEUTIC USE
R Cofﬁ  n, BioVex Ltd, Oxford, OX14 4RX
HSV in which ICP34.5 is deleted gives tumour selective replication in
vitro and in vivo. Such viruses have also proven safe in Phase I clinical
trials by intra-tumoral injection. However, oncolytic HSV containing an
active gene has not previously been tested in man. Previous work has
used serially passaged laboratory isolates of HSV which are attenuated
in tumour cells as compared to clinical isolates. To enhance anti-tumour
properties, we have deleted ICP34.5 from clinical isolates of HSV-1
giving greatly enhanced tumour cell killing. One of these viruses was
then deleted for ICP47 (which blocks antigen presentation) and GM-
CSF inserted to maximize anti-tumour immune responses following
intra-tumoural injection. As expected, the anti-tumour properties of
this virus were greatly improved by each of the modiﬁ  cations. In vivo,
both injected and non-injected tumours could be cured and animals are
protected against further tumour challenge. Following this data, a Phase
I clinical trial with the virus (OncoVEXGM-CSF) is underway including
patients with cutaneous or sub-cutaneous deposits of a number of tumour
types giving promising results so far. In addition, further versions of the
virus expressing other genes have been constructed. These include
viruses expressing TNF∝ and TNF∝ combined with GM-CSF, intended
to be synergistic with radiotherapy, and versions expressing pro-drug
activators and/or a fusogenic glycoprotein to maximize local tumour
control. Each of these have shown promise in pre-clinical models,
including in combination with chemotherapy. In summary, therefore,
continued development of oncolytic HSV has provided a family of
viruses incorporating a range of active genes intended to maximize
the effects of the virus under the different circumstances for which
oncolytic virus therapy might be considered.
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HYPOXIA MEDIATED ALTERATIONS IN THE THRESHOLD FOR 
DRUG-INDUCED APOPTOSIS TUMOURS
Caroline Dive, Janine T Erler and Ian J Stratford, Cellular and 
Molecular Pharmacology Group, Paterson Institute for Cancer 
Research, and School of Pharmacy, University of Manchester.
Drug resistance, an obstacle to curative treatment of solid tumours can 
occur via suppression of apoptosis, a process controlled by pro- and 
anti-apoptotic members of the Bcl-2 family. These proteins integrate 
a variety of cellular survival and stress signals including perturbations 
in oxygen supply and drug-induced damage. Solid tumours with 
disorganised, insufﬁ  cient blood supply contain drug-resistant hypoxic 
cell subpopulations.  We sought to determine the impact of oxygen 
deprivation on Bcl-2 family members and drug response in human colon 
cancer cells. Oxygen deprivation in vitro reduced mRNA and protein 
levels of pro-apoptotic Bid and Bad but had no effect on Bak. Hypoxia 
inducible factor-1 (HIF-1) was dispensable for the down regulation of 
Bad but it was required for Bid down regulation. This was consistent with 
HIF-1 binding to a hypoxia responsive element (-8484 to -8475) in the 
bid promoter.  Oxygen deprivation resulted in proteosome-independent 
Bax down regulation in vitro and a global reduction of translation. The 
physiological relevance of Bid and Bax down-regulation was conﬁ  rmed 
in a xenograft model. Oxygen deprivation resulted in reduced drug-
induced apoptosis and clonogenic resistance to chemotherapeutic drugs 
with disparate mechanisms of action. The functional relevance of Bid 
and/or Bax down-regulation to drug response was evidenced by the 
relative resistance of normoxic cells that had no or reduced expression 
of Bid and/or Bax, and that forced expression of Bid in hypoxic cells 
resulted in increased sensitivity to etoposide. These data add impetus to 
the design of chemotherapeutic strategies to target HIF-1. Experiments 
to evaluate the impact of small molecule inhibitors of HIF-1 function 
on Bcl-2 family regulation of apoptosis in solid tumours are eagerly 
anticipated. 
S6
DETERMINING THE REQUIREMENTS FOR TUMOR MAINTENANCE
IN VIVO
Gerard I. Evan, Lamorna Brown Swigart, Maria Christophorou, Laura Soucek, 
Beth Lawlor, Josina Reddy, Daniel Murphy
UCSF Cancer Center, 2340 Sutter St., San Francisco, California 94143-0875.
Activation of the c-Myc oncoprotein is an archetypical proliferation-deregulating neoplastic 
lesion present in most human tumors. However, c-Myc also has potent apoptotic activity which 
intimates that c-Myc can only drive tumorigenesis in cells in which apoptosis is suppressed. To 
determine the minimal requirements for c-Myc-induced neoplasia in vivo we developed mice in 
which a reversibly switchable c-Myc oncoprotein has been targeted to speciﬁ  c tissues. This allows 
us to explore both the immediate and the delayed consequences of acute activation of c-Myc in 
different somatic settings in vivo, as well as assess the requirement for sustained Myc activation in 
tumor maintenance. When targeted to pancreatic cells, activation of c-Myc in the absence of any 
other oncogenic lesion induces 100% sustained proliferation of all cells in all islets. However, such 
cell proliferation is accompanied by overwhelming apoptosis that rapidly overcomes cell gain and 
expeditiously leads to islet involution and concomitant acute diabetes. This argues that c-Myc-
induced cell neoplasia cannot occur without concomitant suppression of apoptosis. We conﬁ  rmed 
this by co-expressing the anti-apoptotic Bcl-xL protein in   cells, whereupon activation of c-Myc 
triggers rapid, progressive and inexorable  cell neoplasia that was immediately accompanied 
by profound and progressive angiogenesis and invasion. Similarly, activation of c-Myc in cells 
lacking the tumor suppressor p19ARF or p53 triggers immediate tumorigenesis. Subsequent de-
activation of the switchable c-Myc oncoprotein triggers rapid and complete regression of all cell 
tumors, together with their attending vasculature, indicating that Myc is required both to induce 
and to maintain the neoplastic state. Thus, activation of c-Myc is sufﬁ  cient to confer multiple and 
diverse neoplastic traits that become overt only upon suppression of cell death. The immense 
complexity of the tumor phenotype appears to imply that numerous and diverse mutations 
are required for establishment and maintenance of cancers. However, our studies indicate that 
complex neoplastic phenotypes can arise from extremely simple combinations of mutation that, 
minimally, drive sustained cell proliferation and suppress the concomitant apoptosis.
p53 is the apical effector of a pathway that is inactivated in virtually all human cancer. However, 
it remains unclear whether the tumor suppressive action of p53 is mediated through its immediate 
capacity to trigger apoptosis and/or growth arrest, either in response to genotoxic damage 
or growth deregulation activation, or indirectly through maintenance genome integrity and 
suppression of emergent neoplastic mutation. To explore these various roles of p53 in tumor 
suppression and regression in vivo we have constructed a mouse in which the endogenous p53 
gene has been replaced with one encoding an ectopically and reversibly switchable p53 protein. 
Such animals can be rapidly and reversibly toggled between a p53 null and p53 wild type state 
by administration. This model is providing unique insights into the roles of p53 in mediating the 
DNA damage response, suppressing tumorigenesis and maintaining genome integrity in differing 
tissues in vivo. 
S7
THE PROMISE AND CHALLENGE OF TARGETING BCL-2 ANTI-
APOPTOTIC PROTEINS IN CANCER
Jason O’Neill, Michael Manion, Pam Schwartz, David M. Hockenbery. 
Fred Hutchinson Cancer Research Center, Seattle, USA
Cancer cells with elevated levels of BCL-2 and related survival 
proteins are broadly resistant to cytotoxic agents. Antisense 
oligodeoxynucleotides, and more recently small molecule ligands for 
BCL-2 and BCL-XL are directly cytotoxic or synergistic with standard 
cytotoxic agents, and in some cases, appear to have substantial selectivity 
for tumor cells. The usual issues for rational drug discovery are writ 
large upon BCL-2-targeted therapeutics. The molecular functions of 
BCL-2 are not well understood, such that validation of cytotoxicity 
related to BCL-2 as well as identiﬁ  cation of surrogate markers for BCL-
2 function, are signiﬁ  cant obstacles for drug development.  In these 
circumstances, small molecule inhibitors can help to critically evaluate 
current models for BCL-2 survival functions.  An accepted premise 
for protein function in the BCL-2 family is the regulated association 
of survival and pro-apoptotic members as dimers and oligomers, 
employing BH3 domains and BH3-binding pockets on opposing 
subunits.  Instead, the preservation of two binding sites for a BH3-
binding pocket ligand, 2-methoxy antimycin A, in homodimers of BCL-
XL, suggested an alternative dimerization mechanism.  An x-ray crystal 
structure of BCL-XL homodimers reveals a unexpected 3-D domain 
swapping mechanism with exclusion of the BH3-binding pockets from 
the dimer interface.  A second tenet in mammalian apoptotic pathways 
is the dependence of BCL-2 function on the pro-apoptotic BAX and 
BAK proteins.  Though this may be the usual relationship, studies with 
inhibitors show it is not without exception.
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FIBULINS: PHYSIOLOGICAL AND DISEASE PERSPECTIVES
Willam M. Gallagher, Department of Pharmacology, Conway Institute 
of Biomolecular and Biomedical Research, University College Dublin, 
Belﬁ  eld, Dublin 4, Ireland.  e-mail: william.gallagher@ucd.ie
The  ﬁ   bulins are an emerging family of secreted glycoproteins characterised 
by repeated epidermal growth factor-like domains and a unique C-terminal 
structure (1). Members of the ﬁ  bulin family have been associated with a variety 
of physiological and disease processes. Fibulins are thought to serve structural 
roles within the extracellular matrix and have also been shown to modulate cell 
morphology, growth, adhesion and motility to varying extents. Our research to date 
has focused primarily on the role of ﬁ  bulin-1 and –4 in cancer.
Fibulin-4 was originally identiﬁ   ed by our group as a candidate oncogene that 
displays both mutant p53-dependent and -independent oncogenic properties (2). In 
more detail, ectopic overexpression of ﬁ  bulin-4 increased neoplastic transformation 
of rat embryonic ﬁ  broblasts and promoted tumour cell proliferation in vitro. The 
human ﬁ  bulin-4 gene was subsequently localised to 11q13 (3), a region commonly 
ampliﬁ  ed in a variety of human cancers. In addition, ﬁ  bulin-4 was shown to be up-
regulated at the RNA level in normal versus colon tumour biopsies. Preliminary data 
has suggested that ﬁ  bulin-4 may also regulate angiogenesis. However, the functional 
role of ﬁ  bulin-4 in tumours in vivo has yet to be determined.
We have shown that ﬁ  bulin-1, the originator of the family, is increased at the protein 
level in human breast tumours in comparison to normal breast tissue (4). Moreover, 
ﬁ   bulin-1 was aberrantly processed via differential proteolysis in breast cancer 
tissues. Our studies have indicated that ﬁ  bulin-1 may be a useful marker in breast 
cancer. Four alternative splice variants of ﬁ  bulin-1 (-1A to –1D) are known, with the 
–1C and –1D forms being predominantly found. There is now increasing evidence 
to support the hypothesis that ﬁ  bulin-1 is a dual oncogene/tumour suppressor gene, 
with either role dependent on the level and ratio of ﬁ  bulin-1C and –1D splice 
variants present (5). Using both transcriptomic and proteomic techniques, we are 
now attempting to elucidate the molecular basis of the differential effect of ﬁ  bulin-1 
alternative splice variants on tumour-associated activities.
Funding for this work is acknowledged from Enterprise Ireland, the Health Research 
Board of Ireland, the Association for International Cancer Research and the 
European Commission.
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S11
A NEW MOLECULAR TARGET IN COLORECTAL CANCER 
SIGNALLING: THE LKB1 TUMOUR SUPPRESSOR GENE AND 
WNT SIGNALLING
James Spicer1, Sydonia Rayter2 and Alan Ashworth2
1 Department of Medical Oncology, Guy’s Hospital, St Thomas’s Street, 
London SE1 9RT; 2 Breakthrough Breast Cancer Research Centre, 
Institute of Cancer Research, Fulham Road, London SW3 6JB
The study of inherited syndromes of cancer susceptibility has proved
a valuable route to the identiﬁ   cation of many genes involved in
human tumourigenesis. Loss-of-function mutations affecting the
tumour suppressor gene LKB1 cause the Peutz-Jeghers syndrome that
is associated with a greatly increased risk of cancer. LKB1 is also
inactivated in some sporadic tumours, and encodes a serine/threonine
kinase of poorly understood function. Here a new function for LKB1
is suggested. PAR1 is identiﬁ  ed as a protein that is phosphorylated
downstream of the LKB1 kinase. In turn, via its interaction with PAR1,
LKB1 is shown to negatively regulate Wnt signalling. The Wnt pathway,
in which a complex of proteins including APC regulates access of the
transcription factor beta-catenin to the nucleus, is upregulated in most
colorectal tumours. It is proposed that inactivation of LKB1 in PJS
releases Wnt signalling from negative regulation, driving formation of
colorectal and other tumours. A signalling pathway is thus identiﬁ  ed
that provides a rationale for the tumour suppressor activity of LKB1,
and that suggests a novel therapeutic target.
S12
VASCULAR TARGETING STRATEGIES ENHANCE RADIATION 
THERAPY
Dietmar W. Siemann, University of Florida
Given its pivotal role in tumor development, growth and spread, 
considerable efforts have been spent on developing therapeutic 
strategies that compromise the growth and/or function of the tumor 
neovasculature.  Two primary Vascular Targeting Approaches are 
being pursued.  Angiogenic Inhibitors seek to interrupt the process of 
angiogenesis to prevent new tumor blood vessel formation.  Vascular 
Disrupting Agents aim to cause direct damage to the established vessel 
network of actively growing tumors.  Although vascular targeting 
approaches have shown signiﬁ   cant antitumor efﬁ   cacy, when used 
alone, they are unlikely to be curative.  Indeed, their greatest utility 
may ultimately reside in their combination with conventional anticancer 
treatments.  In particular, the application of angiosuppressive or 
vascular disrupting agents might overcome factors known to adversely 
affect the efﬁ  cacy of radiation therapy.  These include the metabolic 
microenvironments associated with the aberrant vascular morphology 
of solid tumors as well as tumor progression and metastatic spread, 
two processes dependent on new blood vessel formation.  Conversely 
radiotherapy may serve to eliminate neoplastic cell populations surviving 
vessel targeting treatment strategies.  This presentation will examine the 
interaction between vascular targeting therapies and radiotherapy and 
explore issues such as timing, sequencing and the potential of achieving 
a therapeutic beneﬁ  t.  Combined modality therapies are a mainstay of 
cancer management and the combination of therapies which target the 
tumor vessel network in conjunction with radiation therapy holds the 
promise of providing signiﬁ  cant improvements in treatment outcomes 
and hence should be thoroughly explored.
S13
HOW TO COMBINE MOLECULAR THERAPEUTICS WITH 
RADIATION: LESSONS FROM PRE-CLINICAL ANIMAL 
MODELS
Kaye J. Williams, School of Pharmacy and Pharmaceutical Sciences, 
University of Manchester, Oxford Road, Manchester, M13 9PL, UK
A great deal of interest surrounds the development of molecular
targeted agents as anti-cancer therapeutics. These have been generated
to inhibit speciﬁ  c components of the pathways that promote the survival
and proliferation of malignant cells. Although some agents may
have utility as stand alone therapies, it is likely that their full clinical
potential will be revealed when they are combined with conventional
therapy and in particular with radiation. The pre-clinical evaluation
of such combinations requires careful consideration, as the inﬂ  uence
of each agent on the underlying factors that govern the success of
radiotherapy has to be addressed. We have evaluated the use of three
molecular targeted agents in a radiotherapy context. ZD1839 (Iressa;
AstraZeneca) and ZD6474 inhibit the tyrosine kinase activities of the
epidermal growth factor receptor and vascular endothelial growth
factor receptor 2 (KDR) respectively. AG14361 is a novel and potent
inhibitor of the DNA-repair enzyme poly(ADP ribose)polymerase.
Despite their diverse molecular targets all three agents successfully
enhance the response of tumour xenografts to radiotherapy. Rational
scheduling designs based upon the potential impact of each agent on
the determinants of radiation response (repopulation, reassortment,
reoxygenation, repair and radiosensitivity) can enhance the efﬁ  cacy of
the combined therapeutic strategies. In addition to targeting molecular
components of the tumour phenotype, tumour speciﬁ  c environmental
conditions can also be exploited. Speciﬁ  cally targeting radioresistant
hypoxic cells within xenograft tumours affords marked enhancement
of radiotherapeutic outcome. These data have clear implications for the
future clinical development of combined schedule approaches.
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COMBINING PLATINUM DRUGS AND RADIATION: 
MECHANISMS AND OUTCOME PREDICTION
ADRIAN C. BEGG
Division of Experimental Therapy, The Netherlands Cancer Institute, 
Plesmanlaan 121, 1066CX Amsterdam
The combination of platinum-containing drugs with radiation therapy 
has become standard treatment for several disease sites and stages. We 
know, however, that not all patients will beneﬁ  t from this combination. 
More information on mechanisms of interaction is needed to choose 
rationally between current treatment options and to design more 
effective schedules. This talk will summarize present knowledge on 
molecular and tissue mechanisms of platinum-radiation interactions, 
and data on predicting outcome of combination treatments. This will 
include which DNA repair pathways are involved, whether lesion bypass 
plays a role, the importance of adduct number and type, the role of GSH, 
and the effect of treatment-induced changes in tumor subpopulations. 
Data showing the predictive power of cisplatin-DNA adducts in 
clinical trials will be shown. Finally I will address questions such as: is 
synergism important? Why should the combination be tumor speciﬁ  c? 
Is the use of platinum drugs in such combination therapies ever likely 
to as effective as molecularly targeted drugs? Is prediction of outcome 
likely to beneﬁ  t the patient population as a whole?
S17
EARLY LUNG TUMOUR DEVELOPMENT: LONGITUDINAL 
STUDIES IN PATIENTS, MODELS IN MICE
Pamela Rabbitts, Department of Oncology, University of Cambridge 
In collaboration with Dr Jeremy George, Middlesex Hospital, London
we are following a cohort of patients at very high risk of lung cancer
development but without detectable tumours at presentation. We use
serial ﬂ  uorescence bronchoscopy to aid the detection of pre-invasive
bronchial lesions which provides us with temporally-related high grade
lesions some of which eventually become invasive tumours. Biopsies of
these lesions are stored both ﬁ  xed and frozen for later extraction of RNA
and DNA following laser capture micro-dissection. We have analysed
samples collected in this way to compare molecular genetic changes
in pre- and post- invasive lesions using loss of heterozygosity analysis,
mutation analysis, comparative genome hybridisation and micro-array
expression analysis.
One of the earliest molecular genetic changes identiﬁ  ed in pre-invasive
bronchial lesions is loss of genetic material from chromosome 3. Using
a positional cloning strategy, we have identiﬁ  ed a candidate tumour
suppressor gene, DUTT1/ROBO1 from within a region of homozygous
loss at 3p12, the smallest deletion being intragenic. To evaluate its role
in tumorigenesis, we have precisely recapitulated this deletion in the
mouse genome. Mice homozygous for this deletion die at birth from
respiratory  failure or later with accompanying bronchial hyperplasia.
Mice heterozygous for the deletion develop lymphomas and lung
adenocarcinomas. The tumours  express virtually no Dutt1/Robo1
protein due to methylation of the gene’s promoter. We conclude that this
gene is acting as a tumour suppressor gene in the development of these
mouse lung tumours. Detailed characterisation of the time course of
development of these mouse tumours should provide insights in to the
very early stages of human lung cancer.
S18
VIDEO-ASSISTED THORACIC SURGERY
David J. Sugarbaker, MD, Brigham and Women’s Hospital, Harvard 
Medical School, Boston, MA 02115.
Minimally invasive techniques have revolutionized the surgical 
approach to the treatment of lung neoplasms. Video-assisted thoracic 
surgery (VATS) techniques have proved indispensable for establishing 
diagnosis of indeterminate pulmonary nodules, and determining stage 
of lung cancer. In high-risk patients with T1 tumors, VATS wedge 
resection has been shown to be a safe and sometimes a deﬁ  nitive 
operation. We recently reported a comparable 5-year survival after 
wedge resection and anatomic resection in a series of 40 patients with 
tumors less than or equal to 1 cm. Despite its versatility, the utility of 
VATS in anatomic lung resections remains controversial.  This is further 
complicated by the fact that the techniques reported in the literature are 
not uniform.  Four different approaches to VATS lobectomy have been 
described. Morbidity and mortality in several published series, however, 
compare favorably to open surgery. The 3-year survival in published 
series for stage I disease ranges from 80% to 94%. The popularity of 
VATS is both surgeon and patient driven and can be attributed to several 
factors: improved postoperative recovery, decreased length of stay, less 
pain, improved pulmonary function, and cosmetically better results. 
Despite these advantages, there is a learning curve associated with 
VATS resections. The VATS approach is contraindicated for centrally 
located tumors and bulky mediastinal disease. However, for a select 
cohort with stage I or early stage II disease without prior therapy, we 
advocate VATS lobectomy as the standard of care. 
S19
RNA POLYMERASE III TRANSCRIPTION – 
A BATTLEGROUND FOR ONCOGENES AND TUMOUR 
SUPPRESSORS 
Robert J. White 
Institute of Biomedical and Life Sciences, Davidson Building, 
University of Glasgow, Glasgow, G12 8QQ, U.K.
Transcription by RNA polymerase III (pol III) is abnormally active in
transformed and tumour cells. Our work aims to characterize the mechanisms
responsible for this deregulation.
The tumour suppressor RB inhibits pol III transcription by binding and
inactivating TFIIIB, a factor which recruits pol III onto promoters.  RB
function is compromised in cancers through one of three mechanisms:
mutation of the Rb gene; hyperphosphorylation by cyclin-dependent kinases;
or binding of oncoproteins.  Each of these mechanisms can derepress TFIIIB
and increase pol III activity. TFIIIB is also bound and repressed by p53 in
healthy cells.  Mutations in p53 contribute to the deregulation of pol III
transcription in some cancers and in Li-Fraumeni syndrome.  Mdm2 and E6
activate pol III transcription by neutralising p53.
As well as being regulated by these tumour suppressors, TFIIIB is also bound
and activated by several oncogenic proteins, including c-Myc, CK2 and the
Erk MAP kinases.  TFIIIB therefore lies at the centre of a complex regulatory
network of conﬂ  icting inﬂ  uences.  The fact that it is targeted directly by
oncoproteins and key tumour suppressors provides a clear indication of the
importance of controlling pol III transcriptional output.
In support of this, pol III-speciﬁ   c transcription factors are frequently
overexpressed in human tumours.  For example, the DNA-binding factor
TFIIIC2, which recruits TFIIIB to promoters, is produced at high levels
in ovarian carcinomas.  HPV16-infected cervical carcinomas overexpress
Brf1, a speciﬁ  c subunit of TFIIIB.  Remarkably, Brf1 overexpression can be
sufﬁ  cient to accelerate cell growth and proliferation.  Clearly, there is strong
selective pressure to raise pol III output during tumour development; this
can be achieved through a range of molecular mechanisms and may have
dramatic effects on proliferative capacity.
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NF-ΚB: TUMOUR PROMOTER OR TUMOUR SUPPRESSOR?
Neil D. Perkins, Division of Gene Regulation and Expression, School 
of Life Sciences, University of Dundee, MSI/WTN Complex, Dow 
Street, Dundee DD1 5EH
Although typically associated with activation by inﬂ  ammatory 
cytokines, NF-κB subunits are also activated by many common cancer 
treatments and can be found aberrantly active in human tumours.  We 
have investigated the relationship between the NF-κB transcription 
factor family and the ARF/p53 tumour suppressor pathway.  In addition, 
we have investigated p53-independent mechanisms regulating NF-
κB function following stimulation with cytotoxic stimuli, including 
chemotherapeutic compounds.  We ﬁ   nd that NF-κB subunits can 
function in two ways.  In one sense, NF-κB subunits behave in an 
oncogenic manner, inducing the expression of anti-apoptotic and pro-
proliferative genes.  In other circumstances, however, the opposite 
occurs and NF-κB subunits actively repress the expression of these 
same target genes.  We have discovered that p53, ARF and some 
chemotherapeutic drugs have the ability to “switch” NF-κB subunits 
from being oncogenic to this more tumour suppressor-like function.   
Taken together, these results indicate that in the early stages of 
oncogenic transformation, NF-κB could act to inhibit tumour growth.   
As tumours develop, however, and tumour suppressor genes become 
inactivated, NF-κB will revert to its oncogenic function.  We suggest 
that care should be taken when designing anti-cancer treatments based 
on inhibition of NF-κB since under some circumstances, NF-κB might 
inhibit rather than stimulate tumour growth.
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TRANSCRIPTIONAL REGULATION BY THE WILMS’ TUMOUR 
SUPPRESSOR PROTEIN WT1.
Kelly Addison, Katherine Boylan, Jörg Hartkamp, Laura Green, Kate 
Wagner and Stefan Roberts. 
Gene Expression and Cell Signalling Laboratories, School of 
Biological Sciences, University of Manchester, Manchester M13 9PT.
Wilms’ tumour is a paediatric malignancy of the kidneys that affects 1 in
10,000 children. The Wilms’ tumour suppressor protein WT1 is mutated
in approximately 15% of Wilms’ tumours, while others show aberrant
WT1 expression. The WT1 protein contains four zinc ﬁ  ngers at its C-
terminus and an N-terminal region that harbours the transcriptional
regulatory domains. The WT1 message is alternatively spliced, which
results in the generation of several isoforms that can have different
physiological effects.WT1 can either activate or repress transcription
and this is dependent upon the isoform of WT1 and the speciﬁ  c cellular
context. Our work concerns the analysis of transcriptional regulation by
WT1 and the interaction partners that modulate WT1 function. We have
found that the apoptosis regulator Par-4 can act as a coactivator for a
speciﬁ  c isoform of WT1 and that this function is required for the ability
of WT1 to mediate cell survival following pro-apoptotic insult. Par-4
can cooperate with WT1 to stimulate transcription of the Bcl2 promoter,
providing a mechanistic basis for this effect. Our current studies
suggest that WT1 isoform imbalance and aberrant Par-4 expression
might be involved in the formation of some Wilms’ tumours. We have
also isolated a transcriptional cosuppressor of WT1, BASP1. BASP1
silences WT1-mediated transcriptional activation. Consistent with this
function, down-regulation of BASP1 by siRNA results in activation of
the amphiregulin promoter by WT1. Amphiregulin is a potent inducer
of kidney tubule branching, suggesting that BASP1 might modulate the
function of WT1 in kidney development. Indeed, BASP1 shows both
temporal and spatial co-expression with WT1 in the embryonic kidney. 
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TARGETING HYPOXIA INDUCIBLE FACTOR-1.
Noan-Minh Chau, Paul Rogers, Wynne Aherne, Ted MacDonald,
Paul Workman, and Margaret Ashcroft. 
Cancer Research UK Centre for Cancer Therapeutics, The Institute of 
Cancer Research, Surrey, United Kingdom.
Hypoxic regions are often found within solid tumours. One of the 
proteins that is induced in response to low oxygen levels is hypoxia 
inducible factor-1α (HIF-1α). In response to hypoxic stress HIF-1α 
dimerises with HIF-1β, a constitutively expressed protein, to form 
the heterodimeric transcription factor, HIF-1. HIF-1 binds to a short 
DNA sequence within the promoter or enhancer region of speciﬁ  c 
target genes. This is called the hypoxia response element (HRE). HIF-1 
target genes include VEGF, glycolytic enzymes, glucose-transporters 
and erythropoietin; these are important in tumour progression and 
metastasis. HIF-1α has been shown to be overexpressed in a number 
of cancers, which is associated with agressive tumours and treatment 
resistance. HIF-1 is an attractive target for therapeutic intervention.
We have generated U2OS human osteosarcoma cells stably expressing 
a luciferase reporter construct under the control of a consensus HRE 
(pGL-HRE). We have used this cell-based system to perform high-
throughput screening to identify compounds that inhibit HIF-1 activity 
induced by treatment with the hypoxia mimetic, DFX (500mM) for
16 hours. Initially, we performed a pilot screen of 4500 compounds, 
which included the NCI ‘Diversity Set’ of 2000 compounds. ‘Hit’ 
compounds from this screen have been evaluated in a variety of 
secondary assays. These studies have indicated that molecular targeting 
of the HIF-1 pathway may be achieved in multiple ways. A large-scale 
screen is complete and we are currently evaluating ‘hit’ compounds. 
This system has proved to be a useful tool to identify HIF-1 inhibitors 
and evaluate compounds that may be therapeutic candidates for drug 
development.
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